Washington wants to decide what drug ads you're allowed to hear
If you’ve ever seen a drug commercial, called your doctor about it, and walked out of that appointment with a better treatment plan, you may soon lose that ability. Not because the drug stopped working or the ad was misleading, but because someone in Washington decided you don’t need to know about it.
TL;DR
- A new proposed rule could significantly impact direct-to-consumer prescription drug advertising.
- The rule, under the guise of 'Transparency in Direct-to-Consumer Advertising,' would mandate the airing of all side effects in broadcast ads.
- This change is anticipated to make ads excessively long and costly, potentially leading to their discontinuation by pharmaceutical companies.
- The FDA estimates this will impose over $100 million in annual costs on advertisers.
- The article suggests this proposal is part of the Trump administration's regulatory agenda.